Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug MK-2828 passes early safety check

NCT ID NCT07089784

Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new medicine called MK-2828 in 46 adults with type 2 diabetes. The main goal was to see if the drug is safe and well-tolerated. Researchers also measured how the drug moves through the body and its effect on a marker of inflammation (hsCRP). This is a first step to see if MK-2828 might help control diabetes in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

46 people

The number who actually took part.

Started

Sep 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * With the exception of type 2 diabetes mellitus (T2DM), is in generally good health * Has a history of T2DM for ≥1 year at the time of screening based on self-reporting * Has a baseline HbA1C level of ≤10% at the time of screening * Has a stable weight (based on self-reporting) defined as ≤5 kg gain or loss of body weight for at least 3 months before Visit 1/Screening * T2DM treated with lifestyle modification alone or with stable doses (no significant change for ≥3 months from Visit 1/Screening, based on self-reporting) of ≤ 3 oral anti-diabetic medications and anticipated not to require dose adjustments during the study duration * Body mass index (BMI) between 25 and 40 kg/m2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has known systemic hypersensitivity to the MK-2828 drug substance or other nucleotide-binding, leucine-rich, protein 3 inhibitor (NLRP3i) based therapy, its inactive ingredients, or the placebo * Has a history of congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4) * Has a history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, unstable peripheral arterial disease and/or stroke within 6 months of screening * History of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food * Has type 1 diabetes mellitus or secondary types of diabetes * Has experienced complications of diabetes such as ketoacidosis, unstable diabetic retinopathy, or maculopathy * Has previous or planned (during the trial period) obesity treatment with surgery or a weight loss device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • AMR Clinical ( Site 0003)

    Knoxville, Tennessee, 37920, United States

  • AMR Lexington ( Site 0012)

    Lexington, Kentucky, 40509, United States

  • Advanced Pharma CR, LLC ( Site 0001)

    Miami, Florida, 33147, United States

  • Alliance for Multispecialty Research, LLC ( Site 0013)

    Kansas City, Missouri, 64114, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009)

    Springfield, Missouri, 65802, United States

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)

    Glendale, California, 91206, United States

  • ICON Early Phase Services ( Site 0006)

    San Antonio, Texas, 78209, United States

  • Jacksonville Center for Clinical Research ( Site 0002)

    Jacksonville, Florida, 32216, United States

  • ProSciento Inc. ( Site 0004)

    Chula Vista, California, 91911, United States

  • QPS Miami Research Associates ( Site 0005)

    South Miami, Florida, 33143, United States

  • Velocity Clinical Research, Hallandale Beach ( Site 0010)

    Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.